IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

Our Fool likes the look of these stock market juggernauts for the chunky passive income they throw off, not to mention their ...

Coca-Cola plans to invest $1 billion in its Nigeria operations over the next five years, the country's presidency said after ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Dr. Beeler's deep industry knowledge and business development prowess will power BPGbio ... Before that, he held various leadership roles at Inivata, bioMerieux, and GSK. He received his Ph.D. in ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

During an investor presentation Thursday, executives admitted to being overly optimistic their vaccine could wrest significant market share away from GSK's and Pfizer's products this year.

British drugmaker GSK on Thursday announced positive results from its mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, saying it would now ...

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza ... the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, ...